Newswise — Queen’s University Belfast, in partnership with the Belfast Trust, is leading the world’s first ever trial of a new combination of cancer therapies for patients with advanced prostate cancer, with the hope of prolonging their lives.
The ADRRAD trial, which recently started at the Northern Ireland Cancer Centre, is funded by and supported by Friends of the Cancer Centre and Bayer Pharmaceuticals.Current picture
In 2014 there were over 1,100 newly diagnosed cases of prostate cancer in Northern Ireland. Almost 8,500 men here are living with a diagnosis of prostate cancer and just under 250 men each year die as a result of the illness.
Thirty patients will participate in the trial over the next 18 months. It is aimed at men with advanced prostate cancer, where the cancer has spread to the bones at the time of diagnosis. This accounts for around 10 per cent of prostate cancer patients.
Men with advanced prostate cancer are normally treated with hormone therapy, which aims to shrink a tumour by limiting the amount of testosterone reaching the cancer cells. The new approach being trialled by Queen’s researchers is the first to combine two existing forms of radiotherapy - Volumetric Modulated Arc Therapy (VMAT) to target prostate cancer cells in the pelvis, along with Radium 223 to target the disease in the bones. If successful, it has the potential to completely change the way in which the disease is treated and potentially extend the life expectancy of patients with the advanced stages of the disease.
VMAT is an advanced type of radiation therapy which manipulates radiation beams to conform to the shape of a tumour, delivering precise radiation doses to a tumour, while minimising the dose to surrounding normal tissue. It is delivered externally, using a radiotherapy machine called a linear accelerator
Radium 223 is a relatively new ‘bone-seeker’ drug. It is a type of internal radiotherapy, which is given intravenously. Once it is in the bones, Radium 223 releases radiation which travels a very short distance - between 2 and 10 cells deep, which is less than a millimetre. This means it delivers a high dose of radiation close to the tumour deposits in the bone, killing the cancer cells and minimising damage to the healthy cells.
Professor Joe O’Sullivan from Queen’s University’s Centre for Cancer Research and Cell Biology and Clinical Director of Oncology in Belfast Trust is leading the trial at the Northern Ireland Cancer Centre at Belfast City Hospital. He said: “This is the first- trial of its kind anywhere in the world. It is hoped that combining the two forms of radiotherapy will be more effective than existing hormone treatment in targeting prostate cancer cells at multiple sites and extend the life expectancy of men whose treatment options are otherwise limited. We expect results from the initial trial within two years, with the view to then embarking on a larger trial with a greater number of patients.
“This trial is a crucial development in the fight against prostate cancer, which is the most common type of cancer among men in Northern Ireland. Three men here are diagnosed with this disease every day. Thousands are living with the illness, which unfortunately claims one life every hour across the UK. Queen’s, Belfast Trust and Northern Ireland are at the forefront of global efforts to develop more effective treatments for all types of cancer. The ADRRAD trial is an excellent example of the potentially life-changing and life-saving impact of this work.”
Colleen Shaw, Chief Executive of Friends of the Cancer Centre said: “Over the last number of years Friends of the Cancer Centre has been working in partnership with Queen’s University to support locally led research and the ADRRAD trial is a great example of the calibre of trials our funding is proudly supporting. “Along with Professor O’Sullivan, Friends of the Cancer Centre’s Consultant Clinical Oncologist, Dr Suneil Jain, and our Research Fellow, Dr Phil Turner, have been heavily involved in the development of this trial and over the next two years the Cancer Centre’s patients will also play a key role in what could be a ground-breaking advancement in prostate cancer treatment. As a local charity powered by the generosity of our supporters, we are very proud to play a part in research that has the potential to benefit not only men in Northern Ireland, but across the world.”The ADRRAD trial is sponsored by Belfast Health and Social Care Trust. Scientific work which takes place alongside the trial is supported by Prostate Cancer UK and the Movember Foundation as part of the Belfast-Manchester Movember Centre of Excellence – a partnership between Queen’s and the University of Manchester.
Dr Iain Frame, Director of Research at Prostate Cancer UK said: “This trial represents a really exciting shift in how we think about prostate cancer – away from aiming to prolong life for men with advanced prostate cancer, towards taking the first steps to stopping the disease in its tracks once and for all. The scale of what we can achieve when we work together as funders, clinicians, scientists and men must not be underestimated. We are on the brink of remarkable breakthroughs in prostate cancer research, and this trial could be one of them.
“That’s why we mustn’t falter now. If we continue investing in world class research like this, within ten years, the world of prostate cancer research and treatment will be a far more hopeful place for men with and at high risk of the disease.”End
Media inquiries to Anne-Marie Clarke (Mon-Wed) or Michelle Cassidy (Thur-Fri) at Queen’s University Communications Office. Tel: +44 (0)28 9097 5310 Email: [email protected]
Notes to editors:1.Professor Joe O’Sullivan is available for interview.2.The full title of the ADRRAD trial is ‘Androgen Deprivation Therapy, Pelvic Radiotherapy and Radium-223 for presentation T1-4 N)/1 M1B adenocarcinoma of prostate’.3.Patients will be selected for the ADRRAD trial following referral through the Uro-oncology Multi-disciplinary Team.4.Prostate cancer in Northern Ireland: Figures from the Northern Ireland Cancer Registry at Queen’s University Belfast http://www.qub.ac.uk/research-centres/nicr/• In 2014 there were over 1,100 newly diagnosed cases of prostate cancer in Northern Ireland.• Currently around 3 new cases of prostate cancer are diagnosed every day in Northern Ireland.• Of those men who are diagnosed, half were over the age of 70.• Almost 8,500 men in Northern Ireland are living with a diagnosis prostate cancer.• Of those living with prostate cancer, 6 out of 10 are over the age of 70.• Just under 250 men in Northern Ireland die as a result of prostate cancer each year. 5. The Centre for Cancer Research and Cell Biology (CCRCB) at Queen's University Belfast is a cross-Faculty, interdisciplinary research centre with over 300 clinical and basic researchers from across the world and is committed to the highest quality of research excellence. To achieve our mission we are pursuing the highest quality clinical and basic science research programmes. The hallmark of our research programme is a close, collaborative interaction between clinical and laboratory research experts that ultimately enhances the quality and scope of our integrated basic and clinical research programmes in cancer as well as other diseases.6.The Northern Ireland Cancer Centre is part of Belfast Trust and provides specialist treatment and support for those with a cancer diagnosis all over Northern Ireland.7.Friends of the Cancer Centre based in the heart of the Cancer Centre at Belfast City Hospital, is the leading local cancer charity in Northern Ireland. The charity works to support cancer patients and families across Northern Ireland by funding life-changing and life-saving projects in three keys areas. They are:i.Clinical care: Friends of the Cancer Centre funds key staff and vital medical equipment throughout the Cancer Centre, including doctors and several specialist cancer nursesii.Patient comfort and care: Friends of the Cancer Centre provides small, everyday comforts throughout the Cancer Centre, including 1000s of newspapers, magazines and cups of tea and coffee; complementary therapy and relaxation classes for over 3,000 patients every year; financial aid for patients and much, much moreiii.Research: Friends of the Cancer Centre is Northern Ireland’s leading charity funding cancer research locally. It is a partner with the Centre for Cancer Research and Cell Biology at Queen’s University, investing nearly £1 million to support life-saving research into clinical trials, which will benefit patient’s right here in Northern Ireland. Find out more www.friendsofthecancercentre.com or queries to Nuala Bannon, Communications Manager 028 9069 9393 or [email protected]